Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
Br J Cancer
; 105(2): 272-80, 2011 Jul 12.
Article
de En
| MEDLINE
| ID: mdl-21712826
ABSTRACT
BACKGROUND:
The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC.METHODS:
The ER+ tumours were classified as 'luminal A' (LA) ER+ and/or PR+, Ki-67 low, p53-, HER2- or 'luminal B' (LB) ER+ and/or PR+and/or Ki-67 high and/or p53+ and/or HER2+. Kaplan-Meier and Cox proportional hazards methodology were used to ascertain relationships to ispilateral breast tumour recurrence (IBTR), locoregional recurrence (LRR), distant metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS).RESULTS:
In all, 73 patients previously LA were re-classified as LB a greater than four-fold increase (4.6-19.3%) compared with ER, PR, HER2 alone. In multivariate analysis, the LB signature independently predicted LRR (hazard ratio (HR) 3.612, 95% CI 1.555-8.340, P=0.003), DMFS (HR 3.023, 95% CI 1.501-6.087, P=0.002) and BCSS (HR 3.617, 95% CI 1.629-8.031, P=0.002) but not IBTR.CONCLUSION:
The prognostic evaluation of ER+ breast cancer is improved using a marker panel, which includes Ki-67 and p53. This may help better define a group of poor prognosis ER+ patients with a greater probability of failure with endocrine therapy.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du sein
/
Carcinomes
/
Récepteurs des oestrogènes
/
Protéine p53 suppresseur de tumeur
/
Antigène KI-67
Type d'étude:
Clinical_trials
/
Evaluation_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Female
/
Humans
/
Middle aged
Langue:
En
Journal:
Br J Cancer
Année:
2011
Type de document:
Article
Pays d'affiliation:
Australie